Physician profile
Ahmad Khattab
NPI 1437569639
$6,751.35
in general payments reported to CMS, 2019-2025
22 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $553 · 2021: $2,272 · 2022: $101 · 2023: $1,021 · 2024: $845 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700 · Travel and Lodging: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.47 |
| Travel and Lodging | $193.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,787.24 | 2021 | |
| Abbott Laboratories | $1,647.77 | 2019-2023 | Proclaim |
| Boston Scientific Corporation | $468.46 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Nevro Corp. | $450.23 | 2019-2024 | Senza, Vyrsa V1 |
| Collegium Pharmaceutical, INC. | $403.49 | 2023-2025 | Belbuca, Xtampza |
| Globus Medical, INC. | $374.82 | 2025 | Corridor, Senza, Vyrsa Fix |
| Spr Therapeutics, INC | $256.69 | 2019-2025 | Sprint Pns System |
| Stryker Corporation | $239.37 | 2023-2025 | Spinejack, Optablate, Mild Device Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.26 | 2023-2025 | Relistor |
| Medtronic, INC. | $180.20 | 2023-2024 | Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $161.83 | 2023-2025 | Evoke, Evoke Scs |
| Si-Bone, INC. | $135.77 | 2023 | |
| Novartis Pharmaceuticals Corporation | $114.12 | 2019 | |
| Scilex Pharmaceuticals INC. | $87.25 | 2022-2024 | |
| Tonix Medicines, INC. | $67.63 | 2025 | Tonmya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $41.77 | 2025 | |
| Valinor Pharma, LLC | $30.99 | 2025 | Movantik |
| Lilly USA, LLC | $24.52 | 2021 | |
| Abbvie INC. | $15.13 | 2021 | |
| Grt US Holding, INC. | $15.12 | 2021 | |
| Zimmer Biomet Holdings, INC. | $14.65 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Daiichi Sankyo INC. | $14.04 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Khattab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.